Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China) ... 05 January, 2022
Oculis Announces Patient Dosing in its First Phase 3 (DIAMOND Study – DIAbetic Macular edema patients ON a Drop) with OCS-01, a Novel, Investigational Topical Eye Drop Treatment for Diabetic Macular Edema (DME) 12 November, 2021
Oculis Appoints Dr. Joanne Chang as Global Chief Medical Officer and Opens Hong Kong Office to broaden its footprint and build a strong Asia/China presence 07 October, 2021
Oculis Announces Positive Data from Two Proof-of-Concept Phase 2 Trials with OCS-02, a Novel Topical TNF alpha Antagonist, in Dry Eye Disease and Acute Anterior Uveitis, Presented at ARVO 2021 11 May, 2021
Oculis to Present Recent Progress in its Portfolio at Upcoming Investor Conferences 24 November, 2020
Oculis recognized as one of the Top 100 Swiss Startups and ranked in Top 10 Biotech 10 September, 2020
